Preclinical studies have shown that Sym004 could effectively inhibit cells stimulated by EGFR ligands and overcome cetuximab resistance mediated by EGFR ECD mutations in CRC [18,147]. The gene discussed is EGFR; the disease is colorectal carcinoma.